Jefferies on Novo Q1: 'Lower End of Guidance Not Lifted More Will Be Seen as Negative' — Sell-Side Counterweight to the Wegovy-Pill Beat
Jefferies analysts pushed back May 6 against the otherwise-positive market reaction to Novo Nordisk's Q1, arguing that the change in full-year guidance (tightened from a 5–13% sales-and-operating-profit decline to a 4–12% decline) was unlikely to lift consensus forecasts and could even contract them: 'we suspect the fact that the company has not lifted the lower end of the guidance range more will be seen as a negative.' The framing matters because NVO US-listed shares had already risen ~6% on the print, and the price-war pressure on the GLP-1 class — with Wegovy pill running at $149/month for the 1.5 mg starter dose against intensifying Foundayo competition — leaves the lower-end risk path open through year-end.